REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...
Update: We spoke with Ashesh Shah, the founder and CEO of the fund leading Bolt’s proposed $450 million raise for some much-needed additional detail on the deal. Read the full interview here. Bolt’s ...
It’s a brutal paradox at the heart of the American EV landscape: We need more affordable options, yet launch a simple, no-frills EV and you’ll struggle to win any buyers. Unfortunately, consumers want ...
Few products attract a cult-like obsession like this one. Even after being off the menu for years, true fans yearn for its return, their devotion bordering on an almost cult-like obsession. Well, they ...
BERKELEY, Calif.--(BUSINESS WIRE)--Bolt Projects Holdings, Inc. (“Bolt,” “Bolt Projects” or the “Company”) (Nasdaq: BSLK), which develops and produces innovative biomaterials for the beauty and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results